Comparison of biological characteristics of mouse bone marrow mesenchymal stem cells after interference and overexpression of telomere Cajal body protein-1

doi:10.12307/2025.686

Abstract

Abstract: BACKGROUND: With the increase of age, the function of bone marrow-derived mesenchymal stem cells is gradually reduced, and delaying the aging of bone marrow-derived mesenchymal stem cells itself has become an important topic.
OBJECTIVE: To explore ways to delay the aging of bone marrow-derived mesenchymal stem cells by changing the expression of telomerase Cajal body protein 1 (TCAB1) gene.
METHODS: Mouse bone marrow-derived mesenchymal stem cells were cultured by cell adhesion method. TCAB1 gene in bone marrow-derived mesenchymal stem cells was overexpressed and interfered by recombinant lentivirus technique. The expression of aging related genes P16, P21, P53, and P27 was detected by qPCR. The relative length of telomeres was detected by qPCR. The expression of aging proteins P16, P21, P53, and P27 was detected by western blot assay. Cell proliferation was detected by CCK-8 assay. Annexin V-PE/7-AAD apoptosis kit was used to detect the degree of cell apoptosis.
RESULTS AND CONCLUSION: Bone marrow-derived mesenchymal stem cell lines overexpressing TCAB1 gene had decreased expression of senescence related genes and proteins, increased Telomere relative length, stronger cell proliferation, less apoptosis, and a youthful state. The expression of age-related genes and proteins in bone marrow mesenchymal stem cells interfering with TCAB1 gene increased, and the relative telomere length decreased; cell proliferation ability was weak; cell apoptosis was more, and cells showed senescence. These results indicate that increasing the expression of TCAB1 in an appropriate range can delay the rate of cell senescence.

Key words: bone marrow mesenchymal stem cell, telomerase Cajal body protein 1, aging, overexpression, interference, cell proliferation, cell apoptosis, engineered stem cell

CLC Number:

Lin Shuqian, Zhao Xilong, Gao Jing, Pan Xinghua, Li Zian, Ruan Guangping. Comparison of biological characteristics of mouse bone marrow mesenchymal stem cells after interference and overexpression of telomere Cajal body protein-1[J]. Chinese Journal of Tissue Engineering Research, 2025, 29(31): 6616-6624.

Figures/Tables 7

References

[1] LI Y, SUN W, LI J, et al. HuR-mediated nucleocytoplasmic translocation of HOTAIR relieves its inhibition of osteogenic differentiation and promotes bone formation. Bone Res. 2023;11(1):53.
[2] ZHAO D, ZHAO H, HE Y, et al. BMSC Alleviates Dry Eye by Inhibiting the ROS-NLRP3-IL-1β Signaling Axis by Reducing Inflammation Levels. Curr Eye Res. 2024;49(7):698-707.
[3] HU M, XING L, ZHANG L, et al. NAP1L2 drives mesenchymal stem cell senescence and suppresses osteogenic differentiation. Aging Cell. 2022;21(2):e13551.
[4] LIU F, YUAN L, LI L, et al. S-sulfhydration of SIRT3 combats BMSC senescence and ameliorates osteoporosis via stabilizing heterochromatic and mitochondrial homeostasis. Pharmacol Res. 2023;192:106788.
[5] KARIMIAN K, GROOT A, HUSO V, et al. Human telomere length is chromosome end-specific and conserved across individuals. Science. 2024;384(6695):533-539.
[6] ROMERO-HARO AÁ, MULDER E, HAUSSMANN MF, et al. The association between age and telomere length is age-dependent: Evidence for a threshold model of telomere length maintenance. J Exp Zool A Ecol Integr Physiol. 2024;341(4):338-344.
[7] GRILL S, NANDAKUMAR J. Molecular mechanisms of telomere biology disorders. J Biol Chem. 2021;296:100064.
[8] GADELHA RB, MACHADO CB, PESSOA FMCP, et al. The Role of WRAP53 in Cell Homeostasis and Carcinogenesis Onset. Curr Issues Mol Biol. 2022;44(11):5498-5515.
[9] EGELBERG M, DE MARCHI T, PEKAR G, et al. Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long-term follow-up of the SweBCG91RT randomized trial. Mol Oncol. 2023;17(10):2029-2040.
[10] WANG Y, WANG H. CCT6A Regulates Cervical Cancer Cell Glycolysis and Proliferation under Hypoxic Conditions via the Telomerase Cajal Body Protein 1/Telomerase Reverse Tranase. Gynecol Obstet Invest. 2024: 1-12. doi: 10.1159/000539042.
[11] NIU J, GAO RQ, CUI MT, et al. Suppression of TCAB1 expression induced cellular senescence by lessening proteasomal degradation of p21 in cancer cells. Cancer Cell Int. 2021;21(1):26.
[12] WANG J, DAI M, XING X, et al. Genomic, epigenomic, and transcriptomic signatures for telomerase complex components: a pan-cancer analysis. Mol Oncol. 2023;17(1):150-172.
[13] QIN J, AUTEXIER C. Regulation of human telomerase RNA biogenesis and localization. RNA Biol. 2021;18(3):305-315.
[14] ZHANG B, WEI X, LI J. Selenomethionine suppresses head and neck squamous cell carcinoma progression through TopBP1/ATR and TCAB1 signaling. Histol Histopathol. 2024;39(7):877-887.
[15] STRELL C, STENMARK TULLBERG A, JETNE EDELMANN R, et al. Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial. Breast Cancer Res Treat. 2021;187(1):45-55.
[16] QUARANTA P, BASSO-RICCI L, JOFRA HERNANDEZ R, et al. Circulating hematopoietic stem/progenitor cell subsets contribute to human hematopoietic homeostasis. Blood. 2024;143(19):1937-1952.
[17] GOODWIN CM, WATERS AM, KLOMP JE, et al. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Cancer Res. 2023;83(1):141-157.
[18] YEH SH, YU JH, CHOU PH, et al. Proliferation and Differentiation Potential of Bone Marrow-Derived Mesenchymal Stem Cells From Children With Polydactyly and Adults With Basal Joint Arthritis. Cell Transplant. 2024;33:9636897231221878.
[19] LONGHURST HJ, LINDSAY K, PETERSEN RS, et al. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med. 2024;390(5):432-441.
[20] PIERCE EA, ALEMAN TS, JAYASUNDERA KT, et al. Gene Editing for CEP290-Associated Retinal Degeneration. N Engl J Med. 2024;390(21): 1972-1984.
[21] WATTS GF, SCHWABE C, SCOTT R, et al. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat Med. 2023;29(9):2216-2223.
[22] VENTHAM NT, KENNEDY NA, KALLA R, et al. Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC). Cell Mol Gastroenterol Hepatol. 2023;16(3):431-450.
[23] COWAN MJ, YU J, FACCHINO J, et al. Lentiviral Gene Therapy for Artemis-Deficient SCID. N Engl J Med. 2022;387(25):2344-2355.
[24] MIER NC, ROPER DK. Effects of an indole derivative on cell proliferation, transfection, and alternative splicing in production of lentiviral vectors by transient co-transfection. PLoS One. 2024;19(6):e0297817.
[25] FURZE RC, MOLNAR J, PARR NJ, et al. Phase 1 and preclinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia. Br J Clin Pharmacol. 2022;88(12):5238-5256.
[26] MUSHER BL, ROWINSKY EK, SMAGLO BG, et al. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024;25(4):488-500.
[27] SULEMAN S, FAWAZ S, ROBERTS T, et al. Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture. J Virol Methods. 2024;325:114884.
[28] LIU S, DENG B, YIN Z, et al. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol. 2021;96(6):671-679.
[29] TASSONE P, DI MARTINO MT, ARBITRIO M, et al. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study. J Hematol Oncol. 2023;16(1):68.
[30] YANG X, FENG Y, LIU Y, et al. Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. Phytomedicine. 2021;87:153575.
[31] SILWAL-PANDIT L, RUSSNES H, BORGEN E, et al. The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer. PLoS One. 2015;10(10):e0139965.
[32] MACHIELS JP, TAO Y, LICITRA L, et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2024;25(5):572-587.
[33] YOO C, LAMARCA A, CHOI HJ, et al. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Future Oncol. 2024; 20(16):1069-1077.